INVO Fertility earnings release, June 2, 2026

INVO Fertility, Inc. (IVF) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

INVO

Fertility Announces Fiscal Year 2025 Financial Results

SARASOTA,

Fla., June

2,

2026 — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results.

FY2025

Financial Highlights

(all metrics compared to FY2024 unless otherwise noted)

Recent

Highlights

Strategic Outlook

Over the past year, INVO Fertility has taken meaningful steps to simplify and strengthen its capital structure. Management believes the Company’s balance sheet is the strongest it has been in more than three years, providing additional optionality to pursue acquisitions from a position of strength, invest in organic growth initiatives, and navigate the market with greater confidence.

The

Company believes fertility care remains supported by favorable long-term demand trends, expanding employer-benefit coverage, increased public awareness around access to care, and a more supportive environment for IVF. INVO’s strategic priorities are centered on driving organic growth across its existing clinics, integrating and expanding Family Beginnings, pursuing disciplined acquisitions that can enhance long-term earnings power, and continuing to expand the commercial and intellectual property value of the INVOcell platform.

Management

Commentary

“This past year marked an important transition for INVO Fertility marked by meaningful progress across operations, acquisitions, and capital structure, positioning the Company for growth through both organic initiatives and strategic clinic acquisitions moving forward,” commented Steve Shum, CEO of INVO Fertility.

“We believe the business has now moved beyond stabilization and into a higher-growth phase. The financing actions completed around year-end and early 2026 improved our flexibility and clarity of capital structure, while the closing of the Family Beginnings acquisition expanded our clinic network to four operational fertility clinics. At the same time, we continue to see attractive opportunities to drive organic growth across our clinics through payer access expansion, added services, operational improvements, and patient-centered innovation.

Importantly, our growing track record as an owner-operator of fertility clinics has enhanced our credibility in the marketplace. As sellers increasingly look for partners who understand both the clinical and operational aspects of fertility care, we believe INVO Fertility stands out as a trusted and capable acquirer.”

“As we look to the future, we are optimistic about what lies ahead. With a stronger operational foundation, a growing clinic network, a robust acquisition pipeline, and the improved balance sheet, INVO Fertility is well positioned for the next chapter of its growth,” Shum concluded.

Use of Non-GAAP Measure

Included in this press release is a reconciliation of Adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

About

INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including

“INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.

Safe

Harbor Statement

Financial statements

Income Statement

For the Year Ended December 31, — CONSOLIDATED STATEMENTS OF OPERATIONS

For the Year Ended December 31, – 2025For the Year Ended December 31, – 2024
Revenue:Clinic revenue6,721,0576,450,431
Revenue:Product revenue120,19381,569
Revenue:Total revenue6,841,2506,532,000
Operating expensesCost of services4,282,1673,645,565
Operating expensesCost of goods sold30,57112,201
Operating expensesSelling, general and administrative7,691,1518,065,801
Operating expensesResearch and development4,880
Operating expensesImpairment of intangible assets1,397,353
Operating expensesLoss on disposal of fixed assets511,663
Operating expensesDepreciation and amortization677,364919,603
Operating expensesTotal operating expenses14,078,60613,159,713
Operating expensesLoss from operations-7,237,356-6,627,713
Other income (expense):Gain (loss) from equity method investment31,2949,045
Other income (expense):Gain on changes in fair value5,172,006
Other income (expense):Gain on lease termination94,551
Other income (expense):Loss from debt extinguishment-2,135,854-40,491
Other income (expense):Loss on issuance of warrants-943,862
Other income (expense):Gain on settlement of liability929,500
Other income (expense):Interest expense-1,302,074-1,035,143
Other income (expense):Total other income (expense )1,751,010-972,038
Other income (expense):Net loss from continuing operations before income taxes-5,486,346-7,599,751
Other income (expense):Provision (benefit) for income taxes-150,371140,202
Other income (expense):Net loss from continuing operations-5,335,975-7,739,953
Other income (expense):Loss on disposition-1,534,517
Other income (expense):Loss from discontinued operations-16,452,562-1,519,000
Other income (expense):Net loss-23,323,054-9,258,953
Other income (expense):Common stock warrants deemed dividends-1,807,170-250,635
Other income (expense):Net loss attributable to common shareholders-25,130,224-9,509,588
Net loss from continuing operations per common share:Basic-45.57-3,078.74
Net loss from continuing operations per common share:Diluted-45.57-3,078.74
Net loss from discontinued operations per common share:Basic-153.63-604.21
Net loss from discontinued operations per common share:Diluted-153.63-604.21
Net loss per common share:Basic-214.64-3,782.65
Net loss per common share:Diluted-214.64-3,782.65
Weighted average number of common shares outstanding:Basic117,0832,514
Weighted average number of common shares outstanding:Diluted117,0832,514
Full release

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform

Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,”

“estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies,... (truncated) results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO

Fertility, Inc.

Steve Shum, CEO

978-878-9505 sshum@invofertility.com

Investor

Contact

Lytham Partners, LLC

Robert Blum

602-889-9700

INVO@lythampartners.com

INVO

FERTILITY, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · INVO Fertility earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.